CA3166828A1 - Methods of treating conditions related to the s1p1 receptor - Google Patents

Methods of treating conditions related to the s1p1 receptor

Info

Publication number
CA3166828A1
CA3166828A1 CA3166828A CA3166828A CA3166828A1 CA 3166828 A1 CA3166828 A1 CA 3166828A1 CA 3166828 A CA3166828 A CA 3166828A CA 3166828 A CA3166828 A CA 3166828A CA 3166828 A1 CA3166828 A1 CA 3166828A1
Authority
CA
Canada
Prior art keywords
compound
individual
pharmaceutically acceptable
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3166828A
Other languages
English (en)
French (fr)
Inventor
Catherine M. CROSBY
Gurpreet Ahluwalia
Andrew Christopher Wesley SELFRIDGE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Publication of CA3166828A1 publication Critical patent/CA3166828A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Heat Treatment Of Sheet Steel (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Steering-Linkage Mechanisms And Four-Wheel Steering (AREA)
CA3166828A 2020-01-06 2021-01-06 Methods of treating conditions related to the s1p1 receptor Pending CA3166828A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062957535P 2020-01-06 2020-01-06
US62/957,535 2020-01-06
PCT/US2021/012367 WO2021142030A1 (en) 2020-01-06 2021-01-06 Methods of treating conditions related to the s1p1 receptor

Publications (1)

Publication Number Publication Date
CA3166828A1 true CA3166828A1 (en) 2021-07-15

Family

ID=76788331

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3166828A Pending CA3166828A1 (en) 2020-01-06 2021-01-06 Methods of treating conditions related to the s1p1 receptor

Country Status (12)

Country Link
US (1) US20230338336A1 (https=)
EP (1) EP4087562A4 (https=)
JP (1) JP2023509698A (https=)
KR (1) KR20220124209A (https=)
CN (1) CN115066242A (https=)
AU (1) AU2021205465A1 (https=)
BR (1) BR112022012846A2 (https=)
CA (1) CA3166828A1 (https=)
IL (1) IL294071A (https=)
MX (1) MX2022008342A (https=)
TW (1) TW202135804A (https=)
WO (1) WO2021142030A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4404930A1 (en) * 2021-09-23 2024-07-31 Bristol-Myers Squibb Company Methods of treating hair-loss disorders with tyk2 inhibitors
KR20240134360A (ko) * 2022-01-13 2024-09-09 아레나 파마슈티칼스, 인크. 호르몬 치료와 조합되어 s1p1 수용체-연관된 장애를 치료하는 데 사용하기 위한 에트라시모드
CN118234492A (zh) * 2022-10-21 2024-06-21 次代生物科学株式会社 具有针对s1pr1和s1pr4的功能性抑制剂作用的用于预防或治疗圆形脱发症的药物组合物
KR102541577B1 (ko) * 2022-10-21 2023-06-13 주식회사 넥스트젠바이오사이언스 S1pr1과 s1pr4에 대한 기능적 저해제로 작용하는 원형 탈모증의 예방 또는 치료용 약학적 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003061567A2 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
US8580841B2 (en) * 2008-07-23 2013-11-12 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
MX2012005560A (es) * 2009-11-13 2012-10-05 Receptos Inc Moduladores selectivos del receptor de esfingosina 1 fosfato y metodos de sintesis quiral.
ES2665461T3 (es) * 2009-11-13 2018-04-25 Celgene International Ii Sàrl Moduladores del receptor esfingosina 1-fosfato y métodos de síntesis quiral
PH12012500940B1 (en) * 2009-11-13 2018-09-26 Receptos Llc Selective heterocyclic sphingosine 1 phosphate receptor modulators
US9198911B2 (en) * 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
PL3242666T3 (pl) * 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
MX2019009841A (es) * 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.

Also Published As

Publication number Publication date
KR20220124209A (ko) 2022-09-13
CN115066242A (zh) 2022-09-16
US20230338336A1 (en) 2023-10-26
MX2022008342A (es) 2022-08-04
EP4087562A1 (en) 2022-11-16
JP2023509698A (ja) 2023-03-09
TW202135804A (zh) 2021-10-01
EP4087562A4 (en) 2024-01-10
AU2021205465A1 (en) 2022-07-14
IL294071A (en) 2022-08-01
WO2021142030A1 (en) 2021-07-15
BR112022012846A2 (pt) 2022-09-06

Similar Documents

Publication Publication Date Title
US20230338336A1 (en) Methods of treating conditions related to the s1p1 receptor
US12097182B2 (en) Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
CN118976023A (zh) 治疗与s1p1受体有关的病况的方法
US20180353487A1 (en) METHODS OF TREATING KERATIN HYPERPROLIFERATION DISORDERS USING mTOR INHIBITORS
AU2024204716A1 (en) Treatment of alopecia areata
EP4395779A1 (en) Lou064 for treating multiple sclerosis
CN120267673A (zh) 用于治疗癌症的剂量方案
TW201938167A (zh) 含有賽度替尼之外用皮膚醫藥組成物及其用途
EP3137088B1 (en) Pharmaceutical packaging for estriol therapy for the treatment of multiple sclerosis
CN113423402A (zh) 癌症治疗
Wernicke et al. Antidepressants: duloxetine at doses of 60 mg QD and 60 mg BID is effective in treatment of diabetic neuropathic pain (DNP)
HK40080125A (en) Methods of treating conditions related to the s1p1 receptor
WO2023183354A1 (en) Blu-945 in combination with osimertinib for the treatment of non-small-cell lung cancer
TW202114656A (zh) 治療與s1p1 受體相關之病況的方法
KR102585038B1 (ko) 렙틴 수용체 길항제 펩타이드를 유효성분으로 함유하는 유방암 치료용 약학적 조성물
HUP0100365A2 (hu) Kombinációs terápia AIDS kezelésére
Wernicke et al. Antidepressants: The safety of duloxetine in the long-term treatment of diabetic neuropathic pain
TW202122086A (zh) 嗜中性白血球彈性蛋白酶抑制劑在肺部疾病中之使用
JP2024537906A (ja) 粘膜炎を処置するための組成物及び方法
HK40085111A (en) Dosage regimen for the treatment of cancer
JP5678566B2 (ja) 乾癬予防治療剤
TW202400145A (zh) 治療ｓ１ｐ受體相關病況之方法
WO2023212812A1 (en) Method and use of psilocybin in the prevention and treatment of stroke
HK1257770B (en) Treatment of alopecia areata
Paul et al. AB0427 Comparative safety of abatacept vs tofacitinib in adults with moderate-to-severe ra: a systematic literature review and network meta-analysis

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251202

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260217